又一“减肥药”，史诗级暴跌

Core Viewpoint - Viking Therapeutics experienced a significant stock drop of nearly 44% following the release of disappointing mid-term trial data for its weight loss drug VK2735, raising concerns about its competitiveness against established players like Eli Lilly and Novo Nordisk [1][3]. Group 1: Company Performance - Viking Therapeutics' stock opened down nearly 44%, marking its largest intraday drop since April 2016 [1]. - The company's market capitalization fell to approximately $2.65 billion after the announcement [2]. - The mid-term trial data indicated that VK2735 helped patients lose up to 12.2% of their weight, with 80% of participants reporting a weight loss of over 10% [3]. Group 2: Clinical Trial Insights - Approximately 28% of patients dropped out of the VK2735 trial within three months, which negatively impacted investor confidence [3]. - In contrast, the previous year, Viking reported positive results from the second phase of VK2735 trials, where patients lost an average of 14.7% of their weight over 13 weeks [4]. Group 3: Industry Context - Eli Lilly's oral weight loss drug Orforglipron also faced scrutiny after its trial results showed a 12.4% average weight loss, leading to a 14% drop in its stock price [6]. - Analysts noted that despite the drop, Eli Lilly's core growth drivers remain strong, and the market reaction may have been an overreaction [6][7].